Lakefront Biotherapeutics NV
No SEC Form 4 filings for $LKFT in the last 30 days.
See all $LKFT insider activity →Lakefront Biotherapeutics (LKFT) repurchased 117,437 of its shares for €3.05M between September 28 and October 2, 2026, as part of a share buyback program announced in June 2026. The company's shares are listed on Euronext and NASDAQ.
Lakefront Biotherapeutics (LKFT) repurchased 106,060 shares for €2.8M between September 21 and 25, 2026, as part of its share buyback program. The average price paid was €26.36 per share. As of September 25, the company holds 1,633,594 of its own shares.
Lakefront Biotherapeutics (LKFT) rose 3.88% to $31.36 after repurchasing 108,679 shares for about EUR 2.61M (EUR 23.16-EUR 25.44) from Sept 14-18. The company now holds 1.53M shares. Volume was 293,922 vs avg 235,203.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LKFT (Lakefront Biotherapeutics NV). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LKFT coverage spans corporate actions, financial news and regulation.
The buyback modestly reduces float and signals confidence, likely providing slight upward pressure on the stock.
The buyback modestly reduces float and signals confidence, likely supporting the stock price in the short term.
Buyback signals confidence and reduces float, modestly supporting price.
Higher target could boost stock.
The upgrade may trigger buying interest and push the stock toward the new target.
AlphAI scores every news story that mentions LKFT with an AI model for sentiment and relevance, and aggregates insider trades from Lakefront Biotherapeutics NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
Lakefront Biotherapeutics (LKFT) repurchased 117,437 of its shares for €3.05M between September 28 and October 2, 2026, as part of a share buyback program announced in June 2026. The company's shares are listed on Euronext and NASDAQ.
2 min readLakefront Biotherapeutics (LKFT) repurchased 106,060 shares for €2.8M between September 21 and 25, 2026, as part of its share buyback program. The average price paid was €26.36 per share. As of September 25, the company holds 1,633,594 of its own shares.
1 min readLakefront Biotherapeutics (LKFT) rose 3.88% to $31.36 after repurchasing 108,679 shares for about EUR 2.61M (EUR 23.16-EUR 25.44) from Sept 14-18. The company now holds 1.53M shares. Volume was 293,922 vs avg 235,203.
1 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readRBC Capital upgraded Lakefront Biotherapeutics (LKFT) to Outperform, raising its price target to $45.00 from $26.00, citing potential in its autoimmune drug gamgertamig. The firm noted clinical and regulatory risks but highlighted the drug's efficacy and safety profile. LKFT's stock currently trades at $30.19, with RBC estimating peak royalties up to $885 million.
2 min readLakefront Biotherapeutics (LKFT) plans to start registrational trials for gamgertamig in 2027, targeting autoimmune diseases like ITP and AIHA. The company acquired the asset from Ouro, citing promising efficacy and safety data. Lakefront expects to end the year with €2 billion in cash and has a share buyback program. The FDA granted Orphan Drug Designation for gamgertamig in three indications.
2 min readLakefront Biotherapeutics (LKFT) plans to start registrational trials for gamgertamig in 2027, following a restructuring and acquisition of assets from Ouro Medicines. Gilead Sciences (GILD) and Lakefront completed the acquisition of Ouro Medicines to expand their inflammation pipeline. Nektar Therapeutics (NKTR) is advancing its immunology and oncology pipeline through research collaborations.
2 min readLakefront Biotherapeutics (LKFT) announced that the U.S. FDA granted Orphan Drug Designation to gamgertamig for treating pemphigus, adding to prior designations for AIHA and ITP. The drug is in Phase 1b trials for autoimmune diseases, with expansion planned in 2027. Lakefront is developing gamgertamig with Gilead Sciences, aiming for registrational studies next year.
2 min readLakefront Biotherapeutics NV (LKFT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after fu
2 min readLakefront Biotherapeutics (LKFT) reported half-year 2026 results and updated its business after completing its Ouro Medicines acquisition with Gilead in June. It forecast at least €1.6B dry powder after funding gamgertamig to first approval, and maintained ~€2B year-end cash and investments guidance, now including a €50M share repurchase. H1 2026 net revenues were €18.6M and net profit was €16.6M.
7 min read
